Silver Book

Silver Book Fact

Gene transfer process treatment for diabetic retinopathy

A gene transfer process that produces a VEGF receptor prevents retinal vascular permeability (RVP) associated with diabetes that could have value in treating diabetic retinopathy.

Ramirez, Mayda, Zhijian Wu, Bibiana Moreno-Carranza, Michael C. Jeziorski, Edith Arnold, Nundehui Diaz-Lezama, Gonzalo Martinez de la Excalera, Peter Colosi, and Carmen Clapp. Vasoinhibin Gene Transfer by Adenoassociated Virus Type 2 Products Against VEGF-and Diabetes-Induced Retinal Vasopermeability. Invest Opthalmol Vis Sci. 2011; 52(12): 8944-8950. http://www.researchgate.net/publication/51720075_Vasoinhibin_Gene_Transfer_by_Adenoassociated_Virus_Type_2_Protects_against_VEGF-_and_Diabetes-Induced_Retinal_Vasopermeability

Reference

Title
Vasoinhibin Gene Transfer by Adenoassociated Virus Type 2 Products Against VEGF-and Diabetes-Induced Retinal Vasopermeability
Publication
Invest Opthalmol Vis Sci
Publication Date
2011
Authors
Ramirez, Mayda, Zhijian Wu, Bibiana Moreno-Carranza, Michael C. Jeziorski, Edith Arnold, Nundehui Diaz-Lezama, Gonzalo Martinez de la Excalera, Peter Colosi, and Carmen Clapp
Volume & Issue
Volume 52, Issue 12
Pages
8944-8950
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Remote Interpretation of Retinal Imaging for DR
    Use of remote interpretation of retinal imaging in diabetics sent via tele-ophthalmology, improved the frequency of screening from 32% to 71% in only 12 months.  
  • Laser Treatment for DR
    Laser treatment of PDR can reduce the 5-year risk of blindness by 90%, and the risk of visual loss from DME by 50%.  
  • Women taking vitamins B6 and B12 and folic acid–as compared to women not taking these supplements–were found to have a 34% lower risk of age-related macular degeneration (AMD) and a…  
  • The NEI-sponsored Ocular Hypertensive Treatment Study (OHTS) found that lowering intraocular pressure (IOP) by at least 20% produced a 50% protective benefit for individuals who had an elevated IOP but…  
  • The cost-effectiveness of detection and treatment of eye disease in diabetics is $3,190 per quality adjusted life year (QALY).